---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Effects of other drugs"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Effects of other drugs. Topics: Strong CYP3A4 inhibitors: predicted exposure; Mineralocorticoid receptor antagonists, potassium-sparing diuretics, and epithelial sodium channel inhibitors: prohibited in the trials; Background renin-angiotensin system inhibitors and SGLT2 inhibitors: serum potassium and eGFR. 3 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Lorundrostat

<a id="topic-2.1.2.9.1-1"></a>

### Strong CYP3A4 inhibitors: predicted exposure

> “is also higher than the high clinical exposure scenario when lorundrostat is given with strong CYP3A4 inhibitors (~1.2-fold increase in Cmax)”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-2.1.2.9.1-2"></a>

### Mineralocorticoid receptor antagonists, potassium-sparing diuretics, and epithelial sodium channel inhibitors: prohibited in the trials

> “The use of epithelial sodium channel inhibitors, MRAs, and potassium-sparing diuretics was prohibited 4 weeks prior to screening to trial completion.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA, estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2, morning serum cortisol level of less than 3 µg/dL, serum sodium level of less than 135 mmol/L, or hemoglobin A1c of 9% or greater.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.1.2.9.1-3"></a>

### Background renin-angiotensin system inhibitors and SGLT2 inhibitors: serum potassium and eGFR

> “were placed on a standardized antihypertensive regimen that included a high-dose angiotensin receptor blocker prior to randomization; greater increases in serum potassium level and decreases in eGFR were observed compared with those in the current trial.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Hyperkalemic events occurred in participants receiving background ACEi/ARB and SGLT2i therapy.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.9.1-4"></a>

### Clinical drug-drug interaction studies

No evidence found.

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
